logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Tafasitamab in combination with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma

< Back

Tafasitamab in combination with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma

Drugs

Cancer and Palliative Care

March 2020


Tafasitamab in combination with lenalidomide is currently in clinical development for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). DLBCL is a type of blood cancer that develops when white blood cells, called lymphocytes, grow out of control. The affected lymphocytes lose their infection-fighting ability making the body more susceptible to infection. The first symptom of DLBCL is often a painful swelling in the neck, armpit or groin but there may be other more general symptoms such as night sweats, unintentional weight loss or high temperature. Relapsed cancer refers to cancer that initially responded to treatment but then returned. Refractory cancer refers to cancer that did not respond to treatment.

Tafasitamab is administered by intravenous infusion and works by blocking the protein CD19 which is widely found on the surface of B-cells (a type of lymphocytes). CD19 is considered important for B-cell signalling and therefore blocking this protein induces death in the cancerous B-cells. Lenalidomide works by altering the activity of the body’s immune system in order to attack abnormal cells. If licenced, tafasitamab Page 2 of 10 in combination with lenalidomide will offer an additional treatment option for patients with relapsed or refractory DLBCL.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts